Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 2
1981 1
1982 1
1983 1
1987 1
1989 1
1990 1
1991 1
1992 1
1994 1
1995 6
1996 2
1997 4
1998 7
1999 6
2000 3
2001 6
2002 6
2003 5
2004 1
2005 8
2006 7
2007 9
2008 7
2009 6
2010 14
2011 12
2012 7
2013 14
2014 13
2015 6
2016 9
2017 10
2018 16
2019 8
2020 13
2021 17
2022 10
2023 11
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Results by year

Filters applied: . Clear all
Page 1
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, Wu X, Cheng R, He W, Yang B, Dong B, Pan J, Chen Y, Huang J, Jiang C, Zhai W, Li F, Chen R, Zhou X, Wu G, Geng X, Chen J, An H, Yuan Y, Xu T, Chen D, Lin D, Xu L, Huang K, Peng L, Yu Y, Tai S, Qi H, Luo K, Kang X, Wang H, Huang Y, Zhang J, Xue W. Xu Y, et al. Eur Urol. 2023 Feb;83(2):163-172. doi: 10.1016/j.eururo.2022.05.029. Epub 2022 Jun 15. Eur Urol. 2023. PMID: 35715365
RESULTS AND LIMITATIONS: A total of 77 patients were identified, including 70 cases with a germline FH alteration (hereditary leiomyomatosis RCC syndrome [HLRCC]-associated RCC) and seven patients with somatic FH loss. ...CONCLUSIONS: We described the genomic characteristi …
RESULTS AND LIMITATIONS: A total of 77 patients were identified, including 70 cases with a germline FH alteration (hereditary leiomyomato …
New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K, Hes O, Williamson SR, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, Humphrey PA, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Gill AJ. Trpkov K, et al. Mod Pathol. 2021 Jul;34(7):1392-1424. doi: 10.1038/s41379-021-00779-w. Epub 2021 Mar 4. Mod Pathol. 2021. PMID: 33664427 Free article.
Papillary RCC subtyping is no longer recommended, as WHO/ISUP grade and tumor architecture better predict outcome. New papillary RCC variants/patterns include biphasic, solid, Warthin-like, and papillary renal neoplasm with reverse polarity. ...The term "fumarate hydratase …
Papillary RCC subtyping is no longer recommended, as WHO/ISUP grade and tumor architecture better predict outcome. New papillary RCC …
Skin manifestations associated with kidney cancer.
Amin A, Burgess EF. Amin A, et al. Semin Oncol. 2016 Jun;43(3):408-12. doi: 10.1053/j.seminoncol.2016.02.016. Epub 2016 Feb 23. Semin Oncol. 2016. PMID: 27178696 Review.
Several therapeutic options based on immunomodulation are approved for the treatment of advanced RCC. Dermatologic toxicities observed with these agents are also briefly discussed....
Several therapeutic options based on immunomodulation are approved for the treatment of advanced RCC. Dermatologic toxicities observed …
Emerging Entities in Renal Neoplasia.
Mehra R, Smith SC, Divatia M, Amin MB. Mehra R, et al. Surg Pathol Clin. 2015 Dec;8(4):623-56. doi: 10.1016/j.path.2015.08.004. Surg Pathol Clin. 2015. PMID: 26612218 Review.
This article reviews emerging entities in renal epithelial neoplasia, including tubulocystic carcinoma, clear-cell-papillary renal cell carcinoma (RCC), thyroid-like follicular RCC, ALK-related RCC, translocation RCC, acquired cystic disease-related RCC, succinate dehydrogenase-d …
This article reviews emerging entities in renal epithelial neoplasia, including tubulocystic carcinoma, clear-cell-papillary renal cell carc …
Molecular and clinicopathologic characterization of intravenous leiomyomatosis.
Ordulu Z, Chai H, Peng G, McDonald AG, De Nictolis M, Garcia-Fernandez E, Hardisson D, Prat J, Li P, Hui P, Oliva E, Buza N. Ordulu Z, et al. Mod Pathol. 2020 Sep;33(9):1844-1860. doi: 10.1038/s41379-020-0546-8. Epub 2020 Apr 27. Mod Pathol. 2020. PMID: 32341498 Free PMC article.
Intravenous leiomyomatosis (IVL) is an unusual uterine smooth muscle proliferation that can be associated with aggressive clinical behavior despite a histologically benign appearance. ...The remaining IVL had nonspecific or no alterations by aCGH. Genomic index scores …
Intravenous leiomyomatosis (IVL) is an unusual uterine smooth muscle proliferation that can be associated with aggressive clinical be …
Hereditary leiomyomatosis and renal cell cancer (HLRCC): Case series and review of the literature.
Yu Y, Zheng M, Zhu W, Zhao F, Guan B, Shen Q, Yang F, He Q, Li X. Yu Y, et al. Urol Oncol. 2021 Nov;39(11):791.e9-791.e16. doi: 10.1016/j.urolonc.2021.07.026. Epub 2021 Aug 27. Urol Oncol. 2021. PMID: 34462205 Review.
BACKGROUND: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant syndrome caused by heterozygous pathogenic germline variants in the fumarate hydratase (FH) gene. ...A novel missense mutation of FH gene (c.454A>G, p.N152D) was predicted …
BACKGROUND: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant syndrome caused by heterozygous pathogen …
Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients.
Seo JY, Ahn JY, Keam B, Kim M, Yoon S, Lee JL, Park K, Park I. Seo JY, et al. Ann Lab Med. 2021 Mar 1;41(2):207-213. doi: 10.3343/alm.2021.41.2.207. Ann Lab Med. 2021. PMID: 33063682 Free PMC article.
BACKGROUND: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant cancer predisposition syndrome. ...No significant genotype-phenotype correlation was observed. CONCLUSIONS: We describe the genotypic and phenotypic spectrum in a small seri …
BACKGROUND: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant cancer predisposition syndrome. ...No si …
Next generation immunohistochemistry: Emerging substitutes to genetic testing?
Andrici J, Gill AJ, Hornick JL. Andrici J, et al. Semin Diagn Pathol. 2018 May;35(3):161-169. doi: 10.1053/j.semdp.2017.05.004. Epub 2017 Jun 27. Semin Diagn Pathol. 2018. PMID: 28662997 Review.
Specifically, we focus on Carney complex, familial adenomatous polyposis (FAP)-associated cribriform-morular variant of papillary thyroid carcinoma, familial succinate dehydrogenase-related pheochromocytoma/paraganglioma syndromes, hereditary leiomyomatosis and renal cell …
Specifically, we focus on Carney complex, familial adenomatous polyposis (FAP)-associated cribriform-morular variant of papillary thyroid ca …
Morphological clues to the appropriate recognition of hereditary renal neoplasms.
Moch H, Ohashi R, Gandhi JS, Amin MB. Moch H, et al. Semin Diagn Pathol. 2018 May;35(3):184-192. doi: 10.1053/j.semdp.2018.01.005. Epub 2018 Feb 14. Semin Diagn Pathol. 2018. PMID: 29454577 Review.
An important emerging role of the surgical pathologist besides the traditional tasks of establishment of the diagnosis and documentation of prognostic and predictive factors, is to recognize the possibility of a hereditary condition in cases where the histology is suggesti …
An important emerging role of the surgical pathologist besides the traditional tasks of establishment of the diagnosis and documentation of …
"Evolution" of intravascular leiomyomatosis.
Chen L, Yang Y, Zhao C. Chen L, et al. BMC Womens Health. 2023 Sep 11;23(1):483. doi: 10.1186/s12905-023-02618-3. BMC Womens Health. 2023. PMID: 37697329 Free PMC article.
BACKGROUND: Intravenous leiomyomatosis (IVL) is a rare and specific type of smooth muscle tumor that is histologically benign but has a malignant biological behavior. ...No surgical-related or anesthesia-related complications occurred.The 3-month follow-up CTV of inferior …
BACKGROUND: Intravenous leiomyomatosis (IVL) is a rare and specific type of smooth muscle tumor that is histologically benign but has …
234 results